BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 15606836)

  • 1. Successful treatment of persistent melanoma in situ with 5% imiquimod cream.
    Muñoz CM; Sánchez JL; Martín-García RF
    Dermatol Surg; 2004 Dec; 30(12 Pt 2):1543-5. PubMed ID: 15606836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream.
    Ray CM; Kluk M; Grin CM; Grant-Kels JM
    Int J Dermatol; 2005 May; 44(5):428-34. PubMed ID: 15869545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of lentigo maligna with imiquimod 5% cream.
    Hopson B; Richey D; Sajben FP
    J Drugs Dermatol; 2007 Oct; 6(10):1037-40. PubMed ID: 17966182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
    Swetter SM; Chen FW; Kim DD; Egbert BM
    J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Outcomes of Melanoma In Situ Treated With Topical 5% Imiquimod Cream: A Retrospective Review.
    Park AJ; Paul J; Chapman MS; Samie FH
    Dermatol Surg; 2017 Aug; 43(8):1017-1022. PubMed ID: 28328708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature.
    Ellis LZ; Cohen JL; High W; Stewart L
    Dermatol Surg; 2012 Jun; 38(6):937-46. PubMed ID: 22338583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod.
    Michalopoulos P; Yawalkar N; Brönnimann M; Kappeler A; Braathen LR
    Br J Dermatol; 2004 Oct; 151(4):903-6. PubMed ID: 15491436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subungual Melanoma In Situ Treated With Imiquimod 5% Cream After Conservative Surgery Recurrence.
    Ocampo-Garza J; Gioia Di Chiacchio N; Haneke E; le Voci F; Paschoal FM
    J Drugs Dermatol; 2017 Mar; 16(3):268-270. PubMed ID: 28301623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imiquimod in the treatment of extensive recurrent lentigo maligna.
    Kamin A; Eigentler TK; Radny P; Bauer J; Weide B; Garbe C
    J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):51-2. PubMed ID: 15692515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of internal melanoma metastases following application of topical imiquimod to overlying skin.
    Miller AK; Dusing R; Meggison A; Aires D
    J Drugs Dermatol; 2011 Mar; 10(3):302-5. PubMed ID: 21369648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of lentigo maligna with imiquimod cream: a long-term follow-up study of 10 patients.
    Van Meurs T; Van Doorn R; Kirtschig G
    Dermatol Surg; 2010 Jun; 36(6):853-8. PubMed ID: 20618370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clearance of invasive melanoma with topical imiquimod.
    Moon SD; Spencer JM
    J Drugs Dermatol; 2013 Jan; 12(1):107-8. PubMed ID: 23377337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
    Wolf IH; Cerroni L; Kodama K; Kerl H
    Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using topical imiquimod for the management of positive in situ margins after melanoma resection.
    Pandit AS; Geiger EJ; Ariyan S; Narayan D; Choi JN
    Cancer Med; 2015 Apr; 4(4):507-12. PubMed ID: 25620351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study of treatment of lentigo maligna with 5% imiquimod cream.
    Fleming CJ; Bryden AM; Evans A; Dawe RS; Ibbotson SH
    Br J Dermatol; 2004 Aug; 151(2):485-8. PubMed ID: 15327559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical imiquimod in the treatment of two cutaneous melanocytomas in a dog.
    Coyner K; Loeffler D
    Vet Dermatol; 2012 Apr; 23(2):145-9, e31. PubMed ID: 21777307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
    Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
    Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of imiquimod for residual acral melanoma.
    Sue GR; Hanlon A; Lazova R; Narayan D
    BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25188932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream.
    van Meurs T; van Doorn R; Kirtschig G
    Dermatol Surg; 2007 May; 33(5):623-6; discussion 626-7. PubMed ID: 17451589
    [No Abstract]   [Full Text] [Related]  

  • 20. Topical imiquimod clears invasive melanoma.
    Grady BE; Spencer JM
    Cutis; 2016 Nov; 98(5):E28-E30. PubMed ID: 28040822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.